FDA Approves Leucovorin for Rare Folate Deficiency, Clarifies It’s Not an Autism Treatment

The Food and Drug Administration (FDA) has approved the apply of leucovorin calcium tablets, marketed as Wellcovorin by GSK, for the treatment of cerebral folate deficiency (CFD). However, the agency has clarified that current evidence does not support the use of leucovorin as a treatment for autism spectrum disorder, despite recent claims suggesting otherwise.

What is Cerebral Folate Deficiency?

Cerebral folate deficiency is a rare neurological condition where folate, a B vitamin, is unable to cross the blood-brain barrier. This deficiency can lead to symptoms such as seizures, motor issues, and intellectual disability Fierce Pharma. The FDA approval specifically targets patients with a confirmed variant in the folate receptor 1 (FOLR1) gene, a very rare genetic form of CFD (FOLR1-CFTD), affecting less than 1 in a million people Fierce Pharma.

Recent Claims and FDA Response

The FDA’s decision comes after U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. Publicly touted leucovorin as a potential therapy for “large numbers of children who suffer from autism” Fierce Pharma. Previously, FDA Commissioner Marty Makary, M.D., stated that leucovorin could potentially benefit “hundreds of thousands of kids” with autism, citing a study where he claimed “two-thirds of kids with autism symptoms had improvement and some marked improvement” Politico.

However, the FDA is now backing away from these broader claims. While acknowledging that some individuals with autism may also have CFD, the agency emphasizes that the approval is specifically for the rare genetic form of the deficiency and is not a cure for autism Politico, Washington Post.

What This Means for Patients

The FDA’s approval expands access to leucovorin for individuals with the specific FOLR1-related CFD. The agency approved the drug without requiring a clinical trial, citing the rarity of the condition Fierce Pharma. However, that this approval does not extend to the broader autism population. Further research is needed to determine if leucovorin has any benefit for individuals with autism, and it should not be considered a standard treatment at this time Axios.

Key Takeaways

• The FDA has approved leucovorin for a rare genetic condition, cerebral folate deficiency (CFD) linked to FOLR1 gene mutations.
• The FDA clarifies that leucovorin is not approved as a treatment for autism spectrum disorder.
• Recent claims about leucovorin’s broad benefits for autism are not supported by current evidence.
• The approved use of leucovorin is for a very compact subset of individuals with CFD, affecting less than 1 in a million people.